Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Retained Earnings (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Retained Earnings for 3 consecutive years, with -$246.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 131.98% to -$246.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$246.2 million through Dec 2025, down 131.98% year-over-year, with the annual reading at -$246.2 million for FY2025, 131.98% down from the prior year.
  • Retained Earnings for Q4 2025 was -$246.2 million at Inhibrx Biosciences, down from -$213.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$14.4 million in Q2 2024, with the low at -$613.7 million in Q4 2023.
  • Average Retained Earnings over 3 years is -$197.5 million, with a median of -$163.8 million recorded in 2025.
  • The sharpest move saw Retained Earnings skyrocketed 82.71% in 2024, then plummeted 1136.78% in 2025.
  • Over 3 years, Retained Earnings stood at -$613.7 million in 2023, then surged by 82.71% to -$106.1 million in 2024, then tumbled by 131.98% to -$246.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$246.2 million, -$213.4 million, and -$178.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.